References
- Khurana A, Sardana K, Chowdhary A. Antifungal resistance in dermatophytes: recent trends and therapeutic implications. Fungal Genet Biol. 2019;132:103255.
- Singh A, Masih A, Monroy-Nieto J, et al. A unique multidrug-resistant clonal Trichophyton population distinct from Trichophyton mentagrophytes/Trichophyton interdigitale complex causing an ongoing alarming dermatophytosis outbreak in India: genomic insights and resistance profile. Fungal Genet Biol. 2019;133:103266.
- Khurana A, Masih A, Chowdhary A, et al. Correlation of in vitro susceptibility based on MICs and squalene epoxidase mutations with clinical response to terbinafine in patients with Tinea Corporis/Cruris. Antimicrob Agents Chemother. 2018;62(12):e01038–18.
- Yamada T, Maeda M, Alshahni MM, et al. Terbinafine resistance of Trichophyton clinical isolates caused by specific point mutations in the squalene epoxidase gene. Antimicrob Agents Chemother. 2017;61:e00115–17.
- Saunte DML, Hare RK, Jørgensen KM, et al. Emerging terbinafine resistance in Trichophyton: clinical characteristics, squalene epoxidase gene mutations, and a reliable EUCAST method for detection. Antimicrob Agents Chemother. 2019;63(10):e01126–19.
- Swaminathan S, Sangwai M, Wawdhane S, et al. Soluble itraconazole in tablet form using disordered drug delivery approach: critical scale-up considerations and bio-equivalence studies. AAPS Pharm Sci Tech. 2013;14(1):360–374.
- Abuhelwa AY, Foster DJR, Mudge S, et al. Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states. Antimicrob Agents Chemother. 2015;59(9):5681–5696.
- Sardana K, Khurana A, Singh A, et al. A pilot analysis of morphometric assessment of itraconazole brands using dermoscopy and its relevance in the current scenario. Indian Dermatol Online J. 2018;9(6):426–431.
- Pasqualotto AC, Denning DW. Generic substitution of itraconazole resulting in sub-therapeutic levels and resistance. Int J Antimicrob Agents. 2007;30(1):93–94.
- Pierard-Franchimont G, De Doncker P, Van de Velde V, et al. PierardGE.Paradoxical response to itraconazole treatment in a patient with onychomycosis caused by Microsporum gypseum. Ann Soc Belg Med Trop. 1995;75(3):211–217.
- Sardana K, Kaur R, Arora P, et al. Is antifungal resistance a cause for treatment failure in dermatophytosis: a study focused on Tinea Corporis and Cruris from a tertiary centre?. Indian Dermatol Online J. 2018;9:90–95.
- Sardana K, Khurana A, Gupta A. Parameters that determine dissolution and efficacy of itraconazole and its relevance to recalcitrant dermatophytoses. Expert Rev ClinPharmacol. 2019;12(5):443–452.
- Noyes AA, Whitney WR. The rate of solution of solid substances in their own solutions. J Am Chem Soc. 1897;19(12):930–934.
- Singh G, Kaur I, Gupta GD, et al. Enhancement of the solubility of poorly water soluble drugs through solid dispersion: a comprehensive review. Indian J Pharm Sci. 2017;79:674–687.
- Brouwers J, Geboers S, Mols R, et al. Gastrointestinal behavior of itraconazole in humans – part 1: supersaturation from a solid dispersion and a cyclodextrin-based solution. Int J Pharm. 2017;525(1):211–217.
- Miller DA, DiNunzio JC, Yang W, et al. Enhanced in vivo absorption of itraconazole via stabilization of supersaturation following acidic-to-neutral pH transition. Drug Dev Ind Pharm. 2008;34(8):890–902.
- Parmentier J, Tan EH, Low A, et al. Downstream drug product processing of itraconazole nanosuspension: factors influencing drug particle size and dissolution from nanosuspension-layered beads. Int J Pharm. 2017;524(1-2):443–453.
- Hattori Y, Haruna Y, Otsuka M. Dissolution process analysis using model-free Noyes-Whitney integral equation. Colloids Surf B Biointerf. 2013;102:227–231.
- Tinke AP, Vanhoutte K, De Maesschalck R, et al. A new approach in the prediction of the dissolution behavior of suspended particles by means of their particle size distribution. J Pharm Biomed Anal. 2005;39(5):900–907.